Newsroom

Our latest developments

Orca Bio’s announcements and press releases

Orca Bio Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T® to Treat Hematological Malignancies

View

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

View

Orca Bio Announces Leadership Updates

View

Orca Bio Announces Positive Results from the Pivotal Phase 3 Study of Investigational Orca-T® Compared to Allogeneic Stem Cell Transplant for the Treatment of Hematologic Malignancies

View

Orca Bio Presents Positive Phase 1 and 1b Data on Orca-T and Orca-Q at the 2025 Tandem Meetings of ASTCT® and CIBMTR®

View

Orca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies

View

Orca Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

View

Orca Bio Presents Three-Year Survival Data with Orca-T® in Patients with Hematological Malignancies at the 66th ASH Annual Meeting

View

Orca Bio's fact sheets

Orca Bio Corporate Overview

View

For media inquiries,

contact us at:

media@orcabio.com
NEXT: Discover who we are